Breaking News

Telix Pharmaceuticals’ Illuccix Granted Marketing Authorization in Germany

Approved for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer.

Author Image

By: Charlie Sternberg

Associate Editor

Telix Pharmaceuticals Limited’s prostate cancer PET imaging agent, Illuccix (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Germany by BfArM for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval enhances the options available to healthcare providers across Germany for PSMA-PET imaging and will ensure more patients can access th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters